I suspect you will say a massive dropoff in sales in 2023, both as COVID rates decline and as insurance companies become much more stringent about when it can be prescribed.
First, COVID is becoming if not is already endemic so there will continue to be a need for anti-virals. Second, vaccination efficacy wanes with time and you can be sure not everyone will be getting boosters so there will be continue to be a need for anti-virals. Third, physicians will be more apt to prescribe anti-virals not less. I know a few younger people who just contracted Covid and felt quite sick. One was prescribed Paxlovid.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.